Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Parkinson’s
Disease Market Outlook
Thelansis’s “Parkinson’s Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026
To 2036” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Parkinson’s
Disease treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Parkinson’s
Disease Overview
Parkinson’s disease (PD) is the second
most prevalent neurodegenerative disorder, characterized by the progressive
loss of dopaminergic neurons in the substantia nigra pars compacta and the
accumulation of misfolded alpha-synuclein into Lewy bodies. This pathology
disrupts basal ganglia motor loops, causing bradykinesia, resting tremor,
rigidity, and postural instability. Genetic risk leans heavily on GBA1 and LRRK2 variants,
alongside rare familial SNCA, PARK2, or PINK1 mutations.
Non-motor symptoms—such as hyposmia, REM sleep behavior disorder, and
depression—frequently emerge years before motor deficits, indicating early
systemic pathology. While diagnosis remains clinical, it is validated by
DaTscan imaging and molecular alpha-synuclein seed amplification assays
(alpha-Syn-SAA). Levodopa is the symptomatic gold standard, though long-term
exposure induces motor fluctuations and dyskinesia. Advanced motor
complications are managed surgically via deep brain stimulation (DBS) or
through continuous delivery systems like Vyalev (foslevodopa-foscarbidopa), an
approved continuous subcutaneous infusion that drastically limits off-time.
However, true disease modification remains a high hurdle; while
anti-alpha-synuclein monoclonal antibodies like Roche’s prasinezumab recently
demonstrated long-term functional benefits in specialized modeling, they
continue to face complex hurdles in late-stage efficacy trials.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment